Point72 Asia Singapore Pte. Ltd. Reduces Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Point72 Asia Singapore Pte. Ltd. lessened its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 12.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 72,863 shares of the company’s stock after selling 10,700 shares during the period. Point72 Asia Singapore Pte. Ltd. owned about 0.11% of Amylyx Pharmaceuticals worth $275,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AMLX. Blue Trust Inc. raised its position in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Amylyx Pharmaceuticals by 12.0% during the fourth quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after purchasing an additional 5,704 shares during the period. Northern Trust Corp boosted its stake in shares of Amylyx Pharmaceuticals by 11.8% during the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after purchasing an additional 11,214 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. Finally, Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Up 3.9%

Amylyx Pharmaceuticals stock opened at $4.52 on Friday. The firm has a market capitalization of $402.92 million, a P/E ratio of -1.18 and a beta of -0.60. The stock has a fifty day moving average price of $4.12 and a 200 day moving average price of $4.21. Amylyx Pharmaceuticals, Inc. has a 52 week low of $1.58 and a 52 week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.03. As a group, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Analyst Ratings Changes

AMLX has been the subject of a number of recent research reports. HC Wainwright boosted their target price on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Leerink Partners raised Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. Leerink Partnrs raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 6th. Finally, Mizuho increased their price target on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $9.83.

Insider Transactions at Amylyx Pharmaceuticals

In related news, CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the completion of the sale, the chief executive officer now directly owns 3,355,280 shares in the company, valued at approximately $11,642,821.60. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bernhardt G. Zeiher bought 10,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were bought at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 48,980 shares of company stock worth $168,627. 11.70% of the stock is currently owned by company insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.